Related Experiment Video
Updated: May 20, 2026
08:34
Isolation of Atrial Myocytes from Adult Mice
Published on: July 25, 2019
Natriuretic peptides and NGAL in heart failure: does a link exist?
Alberto Palazzuoli1, Matteo Beltrami, Marco Pellegrini
1Department of Internal Medicine, UOS Cardiology, S. Maria alle Scotte Hospital Siena, University of Siena, Italy. palazzuoli2@unisi.it
Summary
Biomarkers like B-type natriuretic peptide (BNP) and neutrophil gelatinase-associated lipocalin (NGAL) aid in diagnosing heart failure (HF). Combining BNP and NGAL may improve risk assessment for cardiac and kidney dysfunction in HF patients.
Area of Science:
- Cardiology
- Nephrology
- Clinical Diagnostics
Background:
- Heart failure (HF) diagnosis is challenging due to nonspecific symptoms.
- Biomarkers are increasingly used for HF identification and risk stratification.
- Renal dysfunction frequently complicates HF and predicts poor outcomes.
Purpose of the Study:
- To evaluate the utility of B-type natriuretic peptide (BNP) and neutrophil gelatinase-associated lipocalin (NGAL) in heart failure diagnosis and prognosis.
- To explore the potential of combining BNP and NGAL for enhanced risk assessment.
Main Methods:
- Review of recent literature on natriuretic peptides and NGAL in HF.
- Analysis of diagnostic and prognostic roles of BNP in chronic heart failure (CHF).
- Assessment of NGAL for predicting renal dysfunction in acute and chronic HF.
Main Results:
- BNP is a valuable tool for diagnosing HF and assessing patient outcomes.
- NGAL levels can predict early worsening renal function in acute HF patients.
- NGAL also predicts renal dysfunction in chronic HF patients with preserved renal function.
Conclusions:
- BNP and NGAL are emerging biomarkers for HF diagnosis and prognosis.
- Combining BNP and NGAL may offer a more comprehensive risk assessment for HF patients, identifying those at risk for both cardiac and kidney dysfunction.
Related Concept Videos
01:29Heart Failure II: Pathophysiology
Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
01:22Heart Failure Drugs: Diuretics
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
01:27Transducer Mechanism: Enzyme-Linked Receptors
Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
Major types that are helpful drug targets include:
01:30Heart Failure V: Medical Management
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
01:26Heart Failure Drugs: Inotropic Agents
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...